Abstract: An antisense oligonucleotides having the ability to decrease the expression level of the huntingtin protein in glioma cells, for their use in sensitizing the cells to an anti-cancer treatment.

Abstract: The present invention relates to a device for holding human or animal corneal tissue previously removed for photon treatment thereof with electromagnetic radiation, notable in that the holding device comprises: a stack of elements along a longitudinal axis (A-A?) of the device, said stack comprising: a first plate (1) that is transparent to the electromagnetic radiation, a peripheral seal (4) positioned on the first plate (1), the peripheral seal (4) being intended to extend around the corneal tissue (6), a second plate (2) that is transparent to the electromagnetic radiation on the peripheral seal (4), an immobilizing system (51, 52) for immobilizing the stack of elements and able to press the first and second plates (1, 2) firmly against the corneal tissue in order to apply mechanical stress to the anterior and posterior faces of the corneal tissue.

Abstract: The invention relates to a surgical device to be used in orthopaedic treatment. In particular, the present invention relates to a surgical system for minimally invasive treatment of a trigger finger.

Abstract: A method for determining the operating state of a light-emitting implant implanted in the brain of a living being, the light-emitting implant including a light source responsible for emitting light into the brain of the living being, the method using a diagnosing device that includes a receiver of a light signal transmitted through a first eye of the living being and a device for determining the operating state of the light-emitting implant based on the received transmitted light signal.

Abstract: Collimation device for an X-ray detection system, the collimation device comprising: a collimator comprising a substantially planar support made of a material with partial or zero radiotransparency, the support being rotatably movable about an axis of rotation (?) which passes through the support and which is perpendicular to a first face of the support which acts as an X-ray plane of incidence referred to as the main plane of the support (P), the support (D) being provided on the first face with a slit which is completely transparent to X-rays and which is configured to generate an X-ray flow when the collimator is exposed to an X-ray source, the slit extending longitudinally in the main plane of the support along an axis located at a non-zero distance (d) from the axis of rotation (?), the slit extending through the entire thickness of the support.

Abstract: The present invention relates to an in vitro method for preparing a composition comprising mesenchymal stem cells (MSCs) intended for treating ischemia-reperfusion injury, comprising: a) providing MSCs; b) cultivating MSCs in a culture medium comprising a PPAR?/? agonist; c) removing the culture medium and washing the MSCs; and d) collecting MSCs in a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier does not contain a PPAR?/? agonist. It further relates to MSCs obtained using the method of the invention, as well as their use as a medicament, preferably in the treatment or prevention of ischemia-reperfusion injury, wherein the method of treatment or prevention does not comprise administering a PPAR?/? agonist to the subject.

Abstract: A capsule configured for collecting samples in the intestine, comprising a body delimiting at least one compartment for receiving samples and comprising at least one opening for samples intake, and a mobile mechanism for opening and/or closing the opening controlled by the dissolution of a material which is dissolvable in the intestine.

Abstract: A sleep analyzer, method and system with reduced invasiveness and limited human intervention to monitor sleep in an intensive healthcare unit.

Abstract: The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

Abstract: The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLC?1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an APJ receptor agonist.

Abstract: The invention is directed to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. The present invention further relates to a method for chemically coupling an Adeno-Associated Virus (AAV) vector particle with at least one ligand L and to a Recombinant Adeno-Associated Virus (rAAV) vector particle obtained by said method as well as a pharmaceutical composition comprising it and their corresponding medical use.

Abstract: The present disclosure relates to novel PD-1 decoy variants, compositions, and methods to confer and/or increase immune responses mediated by cellular immunotherapy, such as by adoptively transferring tumor-specific genetically-modified subsets of lymphocytes.

Abstract: The present invention is relative to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antibody or antibody fragment which includes a anti-IL-1RAP binding domain, polypeptides encoded by this nucleic acid molecule, isolated chimeric antigen receptor (CAR) molecule comprising such an antibody or antibody fragment, a vector comprising a nucleic acid molecule encoding a CAR, as well as a T cell comprising this vector. The present invention is also relative to the use of this T cell (autologous or allogeneic) expressing a CAR molecule to treat a proliferative disease in a mammal.

Abstract: A method of predicting the risk of recurrence in a subject undergoing treatment for, or having undergone treatment for, clear cell renal cell carcinoma (ccRCC), by comparing the level of extracellular vesicles, preferably microvesicles, expressing carbonic anhydrase 9 (CA9+ MVs) in a sample from the subject with a reference level. Also, a method of diagnosing ccRCC or identifying a risk of developing ccRCC, by comparing the level of CA9+ MVs in a sample from the subject with a reference level.

Abstract: The present invention relates to a compound of the following general formula (I): or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.

Abstract: Some embodiments are directed to a prognostic method for determining whether a subject is at risk of having the CLAD, comprising: measuring the expression level of POU2AF1 or BLK in a biological sample obtained from the subject; comparing the expression level of POU2AF1 or BLK with a predetermined reference value and concluding that the subject is at risk of having CLAD when the expression level of POU2AF1 or BLK is lower than the predetermined reference value.

Abstract: A compound of general formula (III?), or one of its pharmaceutically acceptable salts, for its use for the treatment of hemophilia in a subject, in particular for the restoration of coagulation in the plasma of a subject suffering from hemophilia, this compound being advantageously administered by oral route:

Abstract: A method for simulating a deep-brain stimulation in a computer-assisted platform that includes providing to a neurosurgeon, through a man-machine interface, visual information of a pre-operative situation, including a representation of a brain. The method also includes monitoring inputs of said neurosurgeon on the man-machine interface, until a trajectory is determined between an entry point and a target for the placement of an electrode. The method further includes comparing said trajectory to a set of previously-established trajectories for the pre-operative situation, so as to determine an overall measurement representative of a quality of the trajectory compared to the previously-established trajectories.

Abstract: The disclosure relates to the use of clofoctol in the prevention or treatment of a disease caused by a coronavirus, in particular Covid-19.